التفاصيل البيبلوغرافية
| العنوان: |
Multicenter Randomized, Double-blind, Placebo-Controlled, Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris. |
| المؤلفون: |
Werth, Victoria P., Fivenson, David, Pandya, Amit G., Chen, Diana, Rico, M. Joyce, Albrecht, Joerg, Jacobus, David |
| المصدر: |
Archives of Dermatology; Jan2008, Vol. 144 Issue 1, p25-32, 8p |
| مستخلص: |
Objective: To determine the efficacy of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris (PV). Design: A randomized, double-blind, placebo-controlled study with a crossover arm for those who failed treatment. Setting: A US multicenter outpatient study. Patients: A total of 19 subjects enrolled among 5 centers, 9 randomized to receive dapsone and 10 to receive placebo. Inclusion criteria were biopsy and direct immunofluorescence-proven PV controlled with glucocorticoids and/or cytotoxic agents, disease in maintenance phase, and aged 18 to 80 years. Physicians had tried at least 2 tapers of glucocorticoids unsuccessfully and had 30 days of stable steroid dosage. Treatment for any patient unable to taper glucocorticoids by more than 25% within 4 months was declared a failure, and the patient was allowed to switch to the opposite medication while maintaining the double-blind. Main Outcome Measure: The ability of patients to taper to 7.5 mg/d or less within 1 year of reaching the maximum dosage of the study drug. Results: Of the 9 patients receiving dapsone, 5 were successfully treated, 3 failed treatment, and 1 dropped out of the study. Of the 10 patients receiving placebo, 3 were successfully treated, and 7 failed treatment. This primary end point favored the dapsone-treated group but was not statistically significant (P = .37). Four patients who failed treatment while receiving placebo were switched to treatment with dapsone. Of these, 3 were successfully treated after switching to dapsone treatment, and 1 failed treatment. We found that, overall, 8 of 11 patients (73%) receiving dapsone vs 3 of 10 (30%) receiving placebo reached the primary outcome of a prednisone dosage of 7.5 mg/d or less. Conclusion: This trial demonstrates a trend to efficacy of dapsone as a steroid-sparing drug in maintenance-phase PV. [ABSTRACT FROM AUTHOR] |
|
Copyright of Archives of Dermatology is the property of American Medical Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
